Alaunos Therapeutics (TCRT) Cash from Operations (2009 - 2026)
Alaunos Therapeutics' (TCRT) quarterly Cash from Operations came in at 1031000.0 in Q1 2026, down 33.55% YoY from 1551524.37 in Q1 2025, and down 86.78% on a QoQ basis from 552000.0 in Q4 2025.
Alaunos Therapeutics (TCRT) Cash from Operations (2009 - 2026) Analysis & Trends
Alaunos Therapeutics (TCRT) has 18 years of Cash from Operations data on file, last reported at 1031000.0 in Q1 2026.
- Quarterly Cash from Operations fell 33.55% year-over-year to 1031000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 3128000.0 (up 18.24% YoY) and the FY2025 annual result came in at 2869000.0, up 42.29% from the prior year.
- Cash from Operations eased to 1031000.0 in Q1 2026, from 552000.0 in the prior quarter.
- In the past five years, Cash from Operations ranged from a high of 552000.0 in Q4 2025 to a low of 9381000.0 in Q1 2023.
- A 5-year average of 4014411.76 and a median of 1917000.0 in 2024 frame the typical range for Cash from Operations.
- Annual changes were most pronounced in 2024 — Cash from Operations surged 91.98% — and 2026, when it tumbled 33.55%.
- Tracing TCRT's Cash from Operations over 5 years: stood at 7130000.0 in 2022, then slipped by 3.58% to 7385000.0 in 2023, then surged by 91.98% to 592000.0 in 2024, then advanced by 6.76% to 552000.0 in 2025, then sank by 86.78% to 1031000.0 in 2026.
- The last three Cash from Operations figures came in at 1031000.0 (Q1 2026), 552000.0 (Q4 2025), and 844000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.13 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 813.00 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -526.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 462.82 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 326.72 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 360.27 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -88.83 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 728.46 Mn |
| 10 | Alaunos Therapeutics | 4.28 Mn | 4.16 Mn | - | -300,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1.03 Mn |
| Mar 31, 2026 | -1.03 Mn |
| Dec 31, 2025 | -552,000.00 |
| Dec 31, 2025 | -552,000.00 |
| Sep 30, 2025 | -844,000.00 |
| Sep 30, 2025 | -844,000.00 |
| Jun 30, 2025 | -701,000.00 |
| Jun 30, 2025 | -701,000.00 |
| Mar 31, 2025 | -772,000.00 |
| Mar 31, 2025 | -772,000.00 |
| Dec 31, 2024 | -592,000.00 |
| Dec 31, 2024 | -592,000.00 |
| Sep 30, 2024 | -781,000.00 |
| Sep 30, 2024 | -781,000.00 |
| Jun 30, 2024 | -1.68 Mn |
| Jun 30, 2024 | -1.68 Mn |
| Mar 31, 2024 | -1.92 Mn |
| Mar 31, 2024 | -1.92 Mn |
| Dec 31, 2023 | -7.39 Mn |
| Dec 31, 2023 | -7.39 Mn |